Loading...
Header Logo
Keywords
Last Name
Institution

LYNETTE MARIE MOORE

TitleInstructor
InstitutionMD Anderson
DepartmentNeurosurgery
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Moore LM, Zhang W. MIR-491: CDKN2A tumor suppressor co-pilot. Oncoscience. 2015; 2(10):825-6. PMID: 26682264.
      View in: PubMed
    2. Li X, Liu Y, Granberg KJ, Wang Q, Moore LM, Ji P, Gumin J, Sulman EP, Calin GA, Haapasalo H, Nykter M, Shmulevich I, Fuller GN, Lang FF, Zhang W. Two mature products of MIR-491 coordinate to suppress key cancer hallmarks in glioblastoma. Oncogene. 2015 Mar 26; 34(13):1619-1628. PMID: 24747968.
      View in: PubMed
    3. Li J, Chen GS, Zhang X, Moore L, Cheng H. Congenital cystic adenomatoid malformation with associated mucinous bronchioloalveolar carcinoma in a neonate. Fetal Pediatr Pathol. 2014 Feb; 33(1):29-34. PMID: 24093545.
      View in: PubMed
    4. Zhang C, Moore LM, Li X, Yung WK, Zhang W. IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma. Neuro Oncol. 2013 Sep; 15(9):1114-26. PMID: 23877318.
      View in: PubMed
    5. Moore LM, Kivinen V, Liu Y, Annala M, Cogdell D, Liu X, Liu CG, Sawaya R, Yli-Harja O, Shmulevich I, Fuller GN, Zhang W, Nykter M. Transcriptome and small RNA deep sequencing reveals deregulation of miRNA biogenesis in human glioma. J Pathol. 2013 Feb; 229(3):449-59. PMID: 23007860.
      View in: PubMed
    6. Holmes KM, Annala M, Chua CY, Dunlap SM, Liu Y, Hugen N, Moore LM, Cogdell D, Hu L, Nykter M, Hess K, Fuller GN, Zhang W. Insulin-like growth factor-binding protein 2-driven glioma progression is prevented by blocking a clinically significant integrin, integrin-linked kinase, and NF-?B network. Proc Natl Acad Sci U S A. 2012 Feb 28; 109(9):3475-80. PMID: 22345562.
      View in: PubMed
    7. Zhang W, Moore L, Ji P. Mouse models for cancer research. Chin J Cancer. 2011 Mar; 30(3):149-52. PMID: 21352691.
      View in: PubMed
    8. Moore LM, Holmes KM, Fuller GN, Zhang W. Oncogene interactions are required for glioma development and progression as revealed by a tissue specific transgenic mouse model. Chin J Cancer. 2011 Mar; 30(3):163-72. PMID: 21352693.
      View in: PubMed
    9. Moore LM, Zhang W. Targeting miR-21 in glioma: a small RNA with big potential. Expert Opin Ther Targets. 2010 Nov; 14(11):1247-57. PMID: 20942748.
      View in: PubMed
    10. Zhou X, Ren Y, Moore L, Mei M, You Y, Xu P, Wang B, Wang G, Jia Z, Pu P, Zhang W, Kang C. Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status. Lab Invest. 2010 Feb; 90(2):144-55. PMID: 20048743.
      View in: PubMed
    11. Higgins RJ, Dickinson PJ, LeCouteur RA, Bollen AW, Wang H, Wang H, Corely LJ, Moore LM, Zang W, Fuller GN. Spontaneous canine gliomas: overexpression of EGFR, PDGFRalpha and IGFBP2 demonstrated by tissue microarray immunophenotyping. J Neurooncol. 2010 May; 98(1):49-55. PMID: 19967449.
      View in: PubMed
    12. Moore LM, Holmes KM, Smith SM, Wu Y, Tchougounova E, Uhrbom L, Sawaya R, Bruner JM, Fuller GN, Zhang W. IGFBP2 is a candidate biomarker for Ink4a-Arf status and a therapeutic target for high-grade gliomas. Proc Natl Acad Sci U S A. 2009 Sep 29; 106(39):16675-9. PMID: 19805356.
      View in: PubMed
    13. Moore L, Lu X, Ghebranious N, Tyner S, Donehower LA. Aging-associated truncated form of p53 interacts with wild-type p53 and alters p53 stability, localization, and activity. Mech Ageing Dev. 2007 Nov-Dec; 128(11-12):717-30. PMID: 18061646.
      View in: PubMed
    14. Gatza C, Moore L, Dumble M, Donehower LA. Tumor suppressor dosage regulates stem cell dynamics during aging. Cell Cycle. 2007 Jan 01; 6(1):52-5. PMID: 17245110.
      View in: PubMed
    15. Dumble M, Moore L, Chambers SM, Geiger H, Van Zant G, Goodell MA, Donehower LA. The impact of altered p53 dosage on hematopoietic stem cell dynamics during aging. Blood. 2007 Feb 15; 109(4):1736-42. PMID: 17032926.
      View in: PubMed
    16. Knisely AS, Strautnieks SS, Meier Y, Stieger B, Byrne JA, Portmann BC, Bull LN, Pawlikowska L, Bilezikçi B, Ozçay F, László A, Tiszlavicz L, Moore L, Raftos J, Arnell H, Fischler B, Németh A, Papadogiannakis N, Cielecka-Kuszyk J, Jankowska I, Pawlowska J, Melín-Aldana H, Emerick KM, Whitington PF, Mieli-Vergani G, Thompson RJ. Hepatocellular carcinoma in ten children under five years of age with bile salt export pump deficiency. Hepatology. 2006 Aug; 44(2):478-86. PMID: 16871584.
      View in: PubMed
    17. Moore L, Venkatachalam S, Vogel H, Watt JC, Wu CL, Steinman H, Jones SN, Donehower LA. Cooperativity of p19ARF, Mdm2, and p53 in murine tumorigenesis. Oncogene. 2003 Oct 30; 22(49):7831-7. PMID: 14586409.
      View in: PubMed
    18. IGFBP2 potentiates nuclear EGFR-STAT3 signaling. Oncogene. 35:738-747.
    19. MIR-491. Oncoscience. 2:825-826.
    20. p53 and Mouse Aging Models. 149-180.
    MOORE's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description